Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting

Julie Valerie Caroline M Decock; Wouter Hendrickx; Raghvendra Mall

Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting

Julie Valerie Caroline M Decock (Inventor), Wouter Hendrickx (Inventor), Raghvendra Mall (Inventor)

QBRI - Cancer Research Center

Qatar Foundation for Education, Science, and Community Development

Research output: Patent

Abstract

The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.

Original language	English
Patent number	US2023348994
IPC	C12Q 1/ 6886 A I
Priority date	28/04/23
Publication status	Published - 2 Nov 2023

Cite this

@misc{299cc23b047f4805b8f590b4fd4a85dc,

title = "Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting",

abstract = "The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.",

author = "Decock, \{Julie Valerie Caroline M\} and Wouter Hendrickx and Raghvendra Mall",

year = "2023",

month = nov,

day = "2",

language = "English",

type = "Patent",

note = "US2023348994; C12Q 1/ 6886 A I",

}

TY - PAT

T1 - Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting

AU - Decock, Julie Valerie Caroline M

AU - Hendrickx, Wouter

AU - Mall, Raghvendra

PY - 2023/11/2

Y1 - 2023/11/2

N2 - The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.

AB - The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.

M3 - Patent

M1 - US2023348994

ER -

Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting

Abstract

Fingerprint

Cite this